MSD terminates Phase II trials for Alzheimer's drug due to liver toxicity - MSN

Sage Therapeutics discontinues dalzanemdor (SAGE-718) development after its Phase II DIMENSION trial failed to meet primary and secondary endpoints in Huntington's disease patients.

The Phase 3 SELECT-MDS-1 trial evaluating tamibarotene plus azacitidine did not meet its primary endpoint of improved complete response (CR) rate in higher-risk myelodysplastic syndrome (HR-MDS) patients.

A phase II trial demonstrated that personalized transcranial magnetic stimulation (TMS) targeting the precuneus significantly slowed clinical decline in mild-to-moderate Alzheimer's disease patients.

Quantum Biopharma's Lucid-21-302, a potential oral treatment for multiple sclerosis (MS), has entered a Phase 1 safety and tolerability trial in healthy adults.

Sanofi has discontinued a Phase 2 clinical trial of oditrasertib, a Denali-partnered drug, for multiple sclerosis after it failed to meet primary or key secondary endpoints.

Sanofi and Denali Therapeutics have discontinued the Phase 2 K2 clinical trial of oditrasertib in multiple sclerosis due to its failure to meet primary and key secondary endpoints.